Press Releases

Press Releases

Date Title
October 23, 2019
Unity Biotechnology, Inc. to Announce Third Quarter 2019 Financial Results
SAN FRANCISCO , Oct. 23, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report results for the third quarter ended September 30,
September 20, 2019
UNITY Biotechnology, Inc. to Participate in the 2019 Cantor Global Healthcare Conference
SAN FRANCISCO , Sept. 20, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate
August 27, 2019
UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Aug. 27, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate at
August 7, 2019
UNITY Biotechnology, Inc. Reports Second Quarter 2019 Financial Results and Program Updates
SAN FRANCISCO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the second quarter ended June 30, 2019 .
July 30, 2019
UNITY Biotechnology, Inc. Announces Plan for Phase 2 Clinical Study of UBX0101 in Osteoarthritis of the Knee
SAN FRANCISCO , July 30, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced details for the planned Phase 2 study of UBX0101 in patients
July 30, 2019
UNITY Biotechnology, Inc. To Announce Second Quarter 2019 Financial Results
SAN FRANCISCO , July 30, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the second quarter ended June 30, 2019 , on
June 18, 2019
UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee
Clinical results support senescent cell elimination with UBX0101 as a potential treatment for osteoarthritis Topline results demonstrate a dose-dependent and clinically meaningful impact on pain Call with management scheduled for today at 8:00 a.m. EDT SAN FRANCISCO , June 18, 2019 (GLOBE NEWSWIRE)
May 29, 2019
UNITY Biotechnology, Inc. and UCSF Enter Exclusive License Agreement on alpha-Klotho Protein for the Treatment of Age-Related Cognitive Decline
UNITY and UCSF continue alpha-Klotho research collaboration that began in 2017 SAN FRANCISCO , May 29, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of
May 23, 2019
UNITY Biotechnology, Inc. to Present at Upcoming Investor Conferences
SAN FRANCISCO , May 23, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate at
May 8, 2019
UNITY Biotechnology, Inc. Reports First Quarter 2019 Financial Results
SAN FRANCISCO , May 08, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported first quarter 2019 financial results.
Displaying 1 - 10 of 17